Linezolid vs no linezolid
Linezolid discontinuationl · drug‐resistant pulmonary tuberculosis
1 finding from 1 review
- no estimate extracted1 study · 65 participantsGRADE not reported
Findings
What do systematic reviews say?
16 questions · 16 findings · 2 reviews
No studies found 6 · 37.5%GRADE not reported 1 · 6.3%Very low 9 · 56.3%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Linezolid vs no linezolid
Death · drug‐resistant pulmonary tuberculosis
It is very uncertain whether linezolid changes death compared with no linezolid (very low certainty).
1 finding from 1 review
- RR 0.65 [0.12, 3.62]1 study · 65 participantsVery low
Linezolid vs no linezolid
Treatment failure · drug‐resistant pulmonary tuberculosis
It is very uncertain whether linezolid changes treatment failure compared with no linezolid (very low certainty).
1 finding from 1 review
- RR 0.26 [0.1, 0.7]1 study · 65 participantsVery low
Linezolid vs no linezolid
Cure · drug‐resistant pulmonary tuberculosis
It is very uncertain whether linezolid changes cure compared with no linezolid (very low certainty).
1 finding from 1 review
- RR 2.36 [1.13, 4.9]1 study · 65 participantsVery low
Linezolid vs no linezolid
Treatment interrupted · drug‐resistant pulmonary tuberculosis
It is very uncertain whether linezolid changes treatment interrupted compared with no linezolid (very low certainty).
1 finding from 1 review
- RR 1.29 [0.31, 5.33]1 study · 65 participantsVery low
Linezolid vs no linezolid
Number of women who completed treatment ‐ total · drug‐resistant pulmonary tuberculosis
It is very uncertain whether linezolid changes treatment completed compared with no linezolid (very low certainty).
1 finding from 1 review
- RR 1.45 [0.45, 4.68]1 study · 65 participantsVery low
Linezolid vs no linezolid
Sputum culture conversion at 8 weeks · drug‐resistant pulmonary tuberculosis
It is very uncertain whether linezolid changes sputum culture conversion at 24 months compared with no linezolid (very low certainty).
1 finding from 1 review
- RR 2.1 [1.3, 3.4]1 study · 65 participantsVery low
Linezolid vs no linezolid
Total adverse eventsg · drug‐resistant pulmonary tuberculosis
1 finding from 1 review
- no estimate extracted1 study · 65 participantsVery low
Linezolid vs no linezolid
Serious adverse events · drug‐resistant pulmonary tuberculosis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Linezolid vs no linezolid
Antituberculous treatment discontinuationj · drug‐resistant pulmonary tuberculosis
It is very uncertain whether linezolid changes antituberculous treatment discontinuationj compared with no linezolid (very low certainty).
1 finding from 1 review
- RR 1.94 [0.18, 20.35]1 study · 65 participantsVery low
Linezolid vs vancomycin
Health‐related quality of life Maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
- Antibiotics for hospital‐acquired pneumonia in neonates and children 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Linezolid vs vancomycin
Mortality (pneumonia-associated) · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
- Antibiotics for hospital‐acquired pneumonia in neonates and children 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Linezolid vs vancomycin
Non‐serious adverse events Maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
- Antibiotics for hospital‐acquired pneumonia in neonates and children 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Linezolid vs vancomycin
All‐cause mortality maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
- Antibiotics for hospital‐acquired pneumonia in neonates and children 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Linezolid vs vancomycin
Serious adverse events maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
- Antibiotics for hospital‐acquired pneumonia in neonates and children 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Linezolid vs vancomycin
Treatment failure Maximum · neonates and children with hospital‐acquired pneumonia
It is very uncertain whether linezolid changes treatment failure Maximum compared with vancomycin (very low certainty).
1 finding from 1 review
- Antibiotics for hospital‐acquired pneumonia in neonates and children 2021 · Cochrane Headline outcomes onlyRR 2.05 [0.49, 8.63]1 study · 32 participantsVery low